Belite Bio (BLTE) IPO More than Doubles on Open
Get Alerts BLTE Hot Sheet
Join SI Premium – FREE
Today's IPO for Belite Bio, Inc (NASDAQ: BLTE) opened trading at $12.50 after pricing 6 million American Depositary Shares (ADSs) at a public offering price per ADS of $6.00.
The Benchmark Company, LLC is acting as sole book-running manager for the offering.
Belite Bio is a San Diego based clinical stage biopharmaceutical drug development company focused on novel therapeutics targeting currently untreatable eye diseases involving retinal degeneration, such as atrophic age-related macular degeneration (commonly known as dry AMD) and autosomal recessive Stargardt disease, and metabolic diseases.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- IMAC Holdings (BACK) halted on volatility, up 26%
- Loar Holdings (LOAR) Announces 11M Share IPO at $24-$26/sh
- Pfizer (PFE) drops to 11-year lows
Create E-mail Alert Related Categories
IPOs, Momentum Movers, Trader TalkRelated Entities
The Benchmark Company, IPOSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!